Escherichia Coli Strain Market

Escherichia Coli Strain Market is Estimated To Witness High Growth Owing To Rising Research and Development Activities


The Escherichia Coli Strain Market is estimated to be valued at US$ 1.97 Bn in 2023 and is expected to exhibit a CAGR of 6.9 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Escherichia coli (E. coli) strain are commonly used in various industries such as biotechnology and pharmaceutical due to their ability to act as hosts for production of recombinant proteins and metabolites. E. coli strain play a vital role in production of enzymes, antibiotics, hormones, vaccines and other therapeutic biomolecules. Due to their fast growth and ease of genetic manipulation, E. coli strains have become integral part of various industrial processes.

Market key trends:

One of the major trend in E. coli strain market is rising research and development activities involving gene cloning and metabolic engineering. The ability of E. coli to act as a host for production of recombinant proteins has led to surge in development of genetically engineered E. coli strains. Researchers are focusing on engineering new E. coli strains with enhanced production capabilities. For instance, genetic engineering of E. coli has enabled industrial scale production of insulin. Similarly, modified E. coli strains are being researched for production of vaccines, biofuels and other high value biomolecules. This rising R&D focus on developing novel E. coli strains tailored for specific applications is driving growth of the market.

Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Escherichia Coli Strain Market is moderate as substantial capital requirements for research and development pose entry barriers.

Bargaining power of buyers: The bargaining power of buyers in the Escherichia Coli Strain Market is high due to availability of alternative strain options.

Bargaining power of suppliers: The bargaining power of suppliers in the Escherichia Coli Strain Market is moderate as a few suppliers dominate the market.

Threat of new substitutes: The threat of new substitutes in the Escherichia Coli Strain Market is low as there are limited strain alternatives available.

Competitive rivalry: Competitive rivalry in the Escherichia Coli Strain Market is high among existing players.

SWOT Analysis
Strength: The Escherichia Coli Strain Market witnesses strong growth due to extensive research and clinical applications of E. coli strains in biologics manufacturing.
Weakness: High costs associated with development of new E. coli strains and regulatory approvals pose challenges. Dependence on government funding also impacts market adversely.
Opportunity: Rising demand for therapeutic antibodies along with recombinant proteins and the need for high-yield production strains present lucrative opportunities.
Threats: Stringent quality regulations and environmental concerns pertaining to genetically modified E. coli limit market potential.

Key Takeaways
Global Escherichia Coli Strain Market Demand is expected to witness high growth, exhibiting CAGR of 6.9% over the forecast period, due to increasing research into development of genetically engineered E. coli strains for production of biopharmaceuticals. North America dominated the market in 2023 with largest market share owing to extensive R&D and presence of major players. Europe is anticipated to grow at fastest pace during the forecast period supported by rising focus of governments in life science sector.

Regional analysis: The Asia Pacific region is projected to witness the highest growth rate over the forecast period owing to rising investments by governments and private players in biomanufacturing industry. Countries such as China, India and South Korea are emerging as lucrative markets.

Key players operating in the Escherichia Coli Strain Market are Thermo Fisher Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation, Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it